Specifically, Ianniello et al. [130] identified that the m6A methyltransferase complex METTL3/METTL14 is highly expressed in CML patients and is essential to maintain the proliferation of primary CML cells and CML cell lines that are sensitive or resistant to tyrosine kinase inhibitors (TKIs) (e.g., imatinib). This evidence concerns the gene METTL3 and chronic myelogenous leukemia, BCR-ABL1 positive.